博时新策略混合A（001522）基金经理为李重阳、罗霄。 截至发稿，李重阳累计任职时间2年345天，现任基金资产总规模11.06亿元，任职期间最佳基金回报 21.67%， 任职期间最差基金回报-19.59%。 罗霄累计任职时间3年110天，现任基金资产总规模187.79亿元，任职期间最佳基金回报34.91%， 任职 期间最差基金回报-0.96%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月16日，一品红跌5.22%，截至发稿，报36.83元/股，成交3.45亿元，换手率2.18%，总市值166.36亿 元。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 从基金十大重仓股角度 数据显 ...

1月15日，一品红跌5.01%，截至发稿，报39.66元/股，成交5.62亿元，换手率3.32%，总市值179.14亿 元。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 华夏新锦汇混合A（004048）成立日期2017年3月8日，最新规模1480.28万。今年以来亏损0.49%，同类 排名8631/8840；近一年收益13.41%，同类排名6028/8094；成立以来收益15.81%。 责任编辑：小浪快报 华夏新锦汇混合A（004048）基金经理为胡杰。 数据显示，华夏基金旗下1只基金重仓一品红。华夏新锦汇混合A（004048）三季度持有股 ...

Group 1 - The core viewpoint of the news is that Yipin Hong's stock has shown volatility with a recent increase in price, but the company faces challenges in revenue and profit margins [1][2]. - As of January 9, Yipin Hong's stock price increased by 2.11% to 36.78 CNY per share, with a total market capitalization of 16.613 billion CNY [1]. - The company has experienced a 9.63% increase in stock price year-to-date, but a significant decline of 33.88% over the past 60 days [1]. Group 2 - For the fiscal year ending December 31, Yipin Hong reported a revenue of 814 million CNY, a decrease of 34.35% year-on-year, while the net profit attributable to shareholders was -136 million CNY, reflecting a growth of 44.80% [2]. - The company has distributed a total of 335 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [3]. - As of September 30, 2025, Yipin Hong's shareholder count increased by 30.22% to 26,500, while the average circulating shares per person decreased by 23.21% to 15,750 shares [2].

1月5日，一品红盘中上涨2.06%，截至09:52，报34.24元/股，成交7085.72万元，换手率0.50%，总市值 154.66亿元。 资金流向方面，主力资金净流入105.71万元，特大单买入0.00元，占比0.00%，卖出190.98万元，占比 2.70%；大单买入1182.72万元，占比16.69%，卖出886.02万元，占比12.50%。 一品红今年以来股价涨2.06%，近5个交易日跌4.01%，近20日跌28.96%，近60日跌39.17%。 机构持仓方面，截止2025年9月30日，一品红十大流通股东中，香港中央结算有限公司位居第七大流通 股东，持股414.96万股，为新进股东。广发医疗保健股票A（004851）位居第九大流通股东，持股 304.52万股，为新进股东。富国精准医疗灵活配置混合A（005176）位居第十大流通股东，持股281.13 万股，为新进股东。易方达医疗保健行业混合A（110023）退出十大流通股东之列。 责任编辑：小浪快报 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：猴痘概念、肝炎治疗、疫 苗、创新药、中药等。 截至11月30日，一品红股东户数2. ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 108.85%, but a recent decline over the past 20 and 60 days, indicating potential concerns about future performance [1][2]. Financial Performance - For the period from January to September 2025, Yipinhong reported a revenue of 814 million yuan, a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million yuan, an increase of 44.80% compared to the previous year [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the last three years [3]. Stock Market Activity - As of December 25, Yipinhong's stock price was 35.63 yuan per share, with a trading volume of 150 million yuan and a market capitalization of 16.094 billion yuan [1]. - The stock has experienced a net outflow of 2.2549 million yuan from major funds, with significant buying and selling activity noted in large orders [1]. Shareholder Information - As of November 30, Yipinhong had 20,400 shareholders, a decrease of 1.73% from the previous period, with an average of 20,511 circulating shares per shareholder, an increase of 1.76% [2]. - New institutional shareholders include Hong Kong Central Clearing Limited and several mutual funds, indicating a shift in the shareholder base [3]. Business Overview - Yipinhong is primarily engaged in the research, production, and sales of its own pharmaceuticals, with a revenue composition of 61.12% from pediatric drugs, 22.71% from chronic disease medications, and 16.17% from other products [1]. - The company operates within the pharmaceutical and biotechnology sector, focusing on chemical pharmaceuticals and various therapeutic areas including hypertension and hepatitis [2].

12月1日，一品红跌5.13%，截至发稿，报48.08元/股，成交2.71亿元，换手率1.32%，总市值217.17亿 元。一品红股价已经连续3天下跌，区间累计跌幅5.73%。 从基金十大重仓股角度 数据显示，博时基金旗下1只基金重仓一品红。博时新策略混合A（001522）三季度持有股数1.76万股， 占基金净值比例为1.85%，位居第七大重仓股。根据测算，今日浮亏损失约4.58万元。连续3天下跌期间 浮亏损失5.42万元。 博时新策略混合A（001522）成立日期2015年11月23日，最新规模5594.69万。今年以来收益7.34%，同 类排名6156/8199；近一年收益7.22%，同类排名6341/8131；成立以来收益50.29%。 博时新策略混合A（001522）基金经理为李重阳、罗霄。 截至发稿，李重阳累计任职时间2年299天，现任基金资产总规模11.06亿元，任职期间最佳基金回报 14.35%， 任职期间最差基金回报-19.59%。 罗霄累计任职时间3年64天，现任基金资产总规模187.79亿元，任职期间最佳基金回报26.8%， 任职期 间最差基金回报-0.96%。 风险提示：市场有风险，投资 ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 182.83%, but a recent decline in the last 20 and 60 days, indicating potential market concerns [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its IPO on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported operating revenue of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several other funds entering the top ten circulating shareholders [3]. Market Activity - On November 19, Yipinhong's stock price fell by 2.01% to 48.25 yuan per share, with a trading volume of approximately 49.77 million yuan and a turnover rate of 0.24%. The total market capitalization is 21.794 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].

今年以来一品红已经5次登上龙虎榜，最近一次登上龙虎榜为7月21日，当日龙虎榜净买入6557.61万 元；买入总计3.05亿元 ，占总成交额比20.96%；卖出总计2.40亿元 ，占总成交额比16.46%。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、DeepSeek概念、 创新药、疫苗、年度强势等。 11月18日，一品红盘中下跌2.02%，截至10:11，报49.00元/股，成交8701.02万元，换手率0.42%，总市 值221.33亿元。 资金流向方面，主力资金净流出211.05万元，特大单买入561.18万元，占比6.45%，卖出0.00元，占比 0.00%；大单买入794.01万元，占比9.13%，卖出1566.23万元，占比18.00%。 一品红今年以来股价 ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 207.74%, but recent trends indicate a decline over the past 60 days [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. It was listed on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported an operating income of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several mutual funds entering the top ten circulating shareholders [3]. Market Activity - On November 14, Yipinhong's stock rose by 2.02%, reaching 52.50 yuan per share, with a trading volume of 165 million yuan and a turnover rate of 0.77%. The total market capitalization is 23.714 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].

Core Viewpoint - Yipinhong's stock price has experienced significant fluctuations, with a year-to-date increase of 186.93% but a recent decline in the last five, twenty, and sixty trading days [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main business revenue composition includes: Children's medicine 61.12%, Chronic disease medicine 22.71%, Others 16.17% [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported operating revenue of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, a year-on-year increase of 44.80% [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed in the last three years [3]. Shareholder Information - As of October 31, the number of Yipinhong's shareholders reached 20,700, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and Guangfa Healthcare Stock A, holding 3.0452 million shares [3].